Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing

British Journal of Haematology

Volumn 146, Issue 4, 2009, Pages 384-395

  Bosanquet, Andrew G ^a   Richards, Sue M ^b   Wade, Rachel ^b   Else, Monica ^c   Matutes, Estella ^c   Dyer, Martin J S ^d   Rassam, Saad M B ^e   Durant, Justin ^a   Scadding, Sheila M ^a   Raper, Steve L ^a   Dearden, Claire E ^c   Catovsky, Daniel ^c  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic drug resistance; Individualised tumour response testing; ITRT; Pentostatin; Tumour response to anti neoplastic compounds assay

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MAFOSFAMIDE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PREDNISOLONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; INDUCED RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES;

EID: 67749129299     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07741.x     Document Type: Article

References (39)

1. Bird, M.C., Bosanquet, A.G., Forskitt, S. Gilby, E.D. (1986) Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in vitro chemosensitivity of haematological malignancies. Leukaemia Research, 10, 445 449.
2. Bland, J.M. Altman, D.G. (1996) Measurement error. British Medical Journal, 313, 744.
3. Bland, J.M. Altman, D.G. (2007) Agreement between methods of measurement with multiple observations per individual. Journal of Biopharmaceutical Statistics, 17, 571 582.
4. Bosanquet, A.G. (1991) Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. The Lancet, 337, 711 714.
5. Bosanquet, A.G. (1994) Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test result with both patient response and survival. Forum Trends in Experimental and Clinical Medicine, 4, 179 198.
6. Bosanquet, A.G. Bell, P.B. (1996) Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leukemia Research, 20, 143 153.
7. Bosanquet, A.G. Bell, P.B. (2004) Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. Journal of Experimental Therapeutics and Oncology, 4, 145 154.
8. Bosanquet, A.G., Kaspers, G.J., Larsson, R., Nagourney, R.A., Nygren, P., Pieters, R., Staib, P., Tidefelt, U., Zwaan, C.M. Weisenthal, L.M. (2007) Individualized tumor response (ITR) profiling for drug selection in tailored therapy: meta-analysis of 1929 cases of leukemia and lymphoma. Blood, 116, 1071A.
9. Bosanquet, A.G., Nygren, P. Weisenthal, L.M. (2008) Individualized tumor response testing in leukemia and lymphoma. In : Innovative leukemia and lymphoma therapy (ed. by G.J. Kaspers, B. Coiffier, M.C. Heinrich E.H. Estey pp. 23 44. Informa Healthcare, New York, NY.
10. Byrd, J.C., Peterson, B., Piro, L., Saven, A., Vardiman, J.W., Larson, R.A. Schiffer, C. (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia, 17, 323 327.
11. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet, 370, 230 239.
12. Cree, I.A. (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Current Opinion in Obstetrics and Gynecology, 21, 39 43.
13. Dearden, C., Wade, R., Else, M., Richards, S., Milligan, D., Hamblin, T. Catovsky, D. (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood, 111, 1820 1826.
14. Else, M., Smith, A.G., Cocks, K., Richards, S.M., Crofts, S., Wade, R. Catovsky, D. (2008) Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. British Journal of Haematology, 143, 690 697.
15. Fiegl, M., Zimmermann, I., Lorenz, I., Hiddemann, W. Braess, J. (2008) In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia. Annals of Hematology, 87, 27 33.
16. Fruehauf, J.P. Bosanquet, A.G. (1993) In vitro determination of drug response: a discussion of clinical applications. Principles and Practice in Oncology Updates, 7, 1 16 (December).
17. Hubeek, I., Peters, G.J., Broekhuizen, R., Zwaan, C.M., Kaaijk, P., van Wering, E.S., Gibson, B.E., Creutzig, U., Janka-Schaub, G.E., den Boer, M.L., Pieters, R. Kaspers, G.J. (2006) In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica, 91, 17 23.
18. Juliusson, G., Elmhorn-Rosenborg, A. Liliemark, J. (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine, 327, 1056 1061.
19. Kay, N.E., Geyer, S.M., Call, T.G., Shanafelt, T.D., Zent, C.S., Jelinek, D.F., Tschumper, R., Bone, N.D., Dewald, G.W., Lin, T.S., Heerema, N.A., Smith, L., Grever, M.R. Byrd, J.C. (2007) Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood, 109, 405 411.
20. Kay, N.E., Wu, W., Byrd, J.C., Kabat, B., Jelinek, D.F., Zent, C.S., Call, T., Lin, T. Shanafelt, T. (2008) Cyclophosphamide remains an important component of treatment in cll patients receiving pentostatin and rituximab based chemoimmunotherapy. Blood, 112, 43a.
21. Kivekas, I., Vilpo, L. Vilpo, J. (2002) Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia. Leukemia Research, 26, 1035 1041.
22. Lamanna, N., Kalaycio, M., Maslak, P., Jurcic, J.G., Heaney, M., Brentjens, R., Zelenetz, A.D., Horgan, D., Gencarelli, A., Panageas, K.S., Scheinberg, D.A. Weiss, M.A. (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 1575 1581.
23. Lane, D.M. (2008). Confidence Interval on Pearson's Correlation. Available at: http://davidmlane.com/hyperstat/B8544.html (accessed on 1 April 2009).
24. Lindhagen, E., Eriksson, A., Wickstrom, M., Danielsson, K., Grundmark, B., Henriksson, R., Nygren, P., Aleskog, A., Larsson, R. Hoglund, M. (2008) Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. European Journal of Haematology, 81, 344 353.
25. Lofgren, C., Albertioni, F. Paul, C. (2005) High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML. Therapeutic Drug Monitoring, 27, 641 646.
26. Nagourney, R.A. (2006) Ex vivo programmed cell death and the prediction of response to chemotherapy. Current Treatment Options in Oncology, 7, 103 110.
27. Nygren, P. Larsson, R. (2008) Predictive tests for individualization of pharmacological cancer treatment. Expert Opinion on Medical Diagnostics, 2, 1 12.
28. O'Brien, S., Kantarjian, H., Estey, E., Koller, C., Robertson, B., Beran, M., Andreeff, M., Pierce, S. Keating, M. (1994) Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. New England Journal of Medicine, 330, 319 322.
29. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414 1420.
30. Pettitt, A.R. (2003) Mechanism of action of purine analogues in chronic lymphocytic leukaemia. British Journal of Haematology, 121, 692 702.
31. Reynolds, C., Di Bella, N., Lyons, R.M., Hyman, W.J., Lee, G.L., Richards, D.A., Robbins, G.J., Vellek, M., Boehm, K.A., Zhan, F. Asmar, L. (2008) Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood, 112, 327a.
32. Robak, T., Lech-Maranda, E., Korycka, A. Robak, E. (2006) Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Current Medicinal Chemistry, 13, 3165 3189.
33. Sellick, G.S., Wade, R., Richards, S., Oscier, D.G., Catovsky, D. Houlston, R.S. (2008) Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood, 111, 1625 1633.
34. Shanafelt, T.D., Lin, T., Geyer, S.M., Zent, C.S., Leung, N., Kabat, B., Bowen, D., Grever, M.R., Byrd, J.C. Kay, N.E. (2007) Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer, 109, 2291 2298.
35. Styczynski, J., Wysocki, M., Debski, R., Czyzewski, K., Balwierz, W., Juraszewska, E., Matysiak, M., Malinowska, I., Stanczak, E., Sonta-Jakimczyk, D., Szczepanski, T., Wachowiak, J., Konatkowska, B., Balcerska, A., Ploszynska, A., Kowalczyk, J., Stefaniak, J., Badowska, W., Wieczorek, M., Olejnik, I., Krawczuk-Rybak, M. Kuzmicz, M. (2005) In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma, 52, 74 78.
36. Tietjen, G.L. (1986) A Topical Dictionary of Statistics, p. 14. Chapman & Hall, London.
37. Weisenthal, L.M., Marsden, J.A., Dill, P.L. Macaluso, C.K. (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Research, 43, 749 757.
38. Weiss, M.A., Maslak, P.G., Jurcic, J.G., Scheinberg, D.A., Aliff, T.B., Lamanna, N., Frankel, S.R., Kossman, S.E. Horgan, D. (2003) Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 21, 1278 1284.
39. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070 4078. (Pubitemid 46211312)